A Potential Approach of Mesenchymal Stem Cells Combined Silybin for Synergistic Treatment in Rheumatoid Arthritis via ICOS/ICOSL

Abstract

Achieving clinical remission in rheumatoid arthritis (RA) remains a significant challenge in current therapeutic strategies. While transplantation of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) has shown promising outcomes, therapeutic responses vary considerably among patients. In this study, we characterized the immune profiles of nonresponders and identified elevated expression of inducible costimulator (ICOS) in peripheral immune cells as a critical barrier to effective treatment. This upregulation, combined with the presence of ICOS ligand (ICOSL) on UC-MSCs, activated T cells to secrete inflammatory cytokines through the Phosphatidylinositol 3-kinase / Protein kinase B / Mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. To overcome this limitation, we identified silybin as a potential adjunctive agent. Further investigations demonstrated that silybin acts as a competitive binding inhibitor, effectively targeting the PI3K/AKT/mTOR pathway and reducing downstream cytokine release. The combined application of silybin and UC-MSCs significantly enhanced immunoregulatory effects, as validated through in vitro analyses with patient-derived samples and in vivo experiments using a collagen-induced arthritis mouse model. This study highlights a novel, personalized therapeutic approach for RA, offering insights into improving clinical outcomes through targeted interventions.

Keywords

ICOS/ICOSL / rheumatoid arthritis / silybin / UC-MSCs

References

[1] J. S. Smolen, G. R. Burmester, B. Combe, et al., “Head-to-head Comparison of certolizumab pegol versus adalimumab in Rheumatoid Arthritis: 2-year Efficacy and Safety Results From the Randomised EXXELERATE Study,” Lancet 388, no. 10061 (2016): 2763-2774.

[2] A. Winkvist, L. Barebring, I. Gjertsson, L. Ellegard, and H. M. Lindqvist, “A Randomized Controlled Cross-Over Trial Investigating the Effect of Anti-inflammatory Diet on Disease Activity and Quality of Life in Rheumatoid Arthritis: The Anti-inflammatory Diet in Rheumatoid Arthritis (ADIRA) Study Protocol,” Nutr J 17, no. 1 (2018): 44.

[3] J. S. Smolen, D. Aletaha, and I. B. McInnes, “Rheumatoid Arthritis,” Lancet 388, no. 10055 (2016): 2023-2038.

[4] D. Wang, S. Huang, X. Yuan, et al., “The Regulation of the Treg/Th17 Balance by Mesenchymal Stem Cells in human Systemic Lupus Erythematosus,” Cell Mol Immunol 14, no. 5 (2017): 423-431.

[5] D. M. Hoang, P. T. Pham, T. Q. Bach, et al., “Stem Cell-based Therapy for human Diseases,” Signal Transduct Target Ther 7, no. 1 (2022): 272.

[6] Z. Zhang, S. Huang, S. Wu, et al., “Clearance of Apoptotic Cells by Mesenchymal Stem Cells Contributes to Immunosuppression via PGE2,” EBioMedicine 45 (2019): 341-350.

[7] D. Wang, X. Feng, L. Lu, et al., “A CD8 T Cell/Indoleamine 2,3-dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of human Systemic Lupus Erythematosus,” Arthritis Rheumatol 66, no. 8 (2014): 2234-2245.

[8] Y. Yang, X. He, R. Zhao, et al., “Serum IFN-gamma Levels Predict the Therapeutic Effect of Mesenchymal Stem Cell Transplantation in Active Rheumatoid Arthritis,” Journal of translational medicine 16, no. 1 (2018): 165.

[9] H. Chen, X. Wen, S. Liu, et al., “Dissecting Heterogeneity Reveals a Unique BAMBI(high) MFGE8(high) Subpopulation of Human UC-MSCs,” Adv Sci (Weinh) 10, no. 1 (2022): e2202510.

[10] D. Wang, S. Wang, S. Huang, et al., “Serum IFN-gamma Predicts the Therapeutic Effect of Mesenchymal Stem Cells Transplantation in Systemic Lupus Erythematosus Patients,” Stem Cells Transl Med 6, no. 9 (2017): 1777-1785.

[11] Y. O. Kim, H. J. Kim, S. K. Kim, J. H. Chung, and S. J. Hong, “Association of the CD28/CTLA4/ICOS Polymorphisms With Susceptibility to Rheumatoid Arthritis,” Clinical Chemistry and Laboratory Medicine 48, no. 3 (2010): 345-353.

[12] V. Panneton, S. Bagherzadeh Yazdchi, M. Witalis, J. Chang, and W. K. Suh, “ICOS Signaling Controls Induction and Maintenance of Collagen-Induced Arthritis,” Journal of Immunology 200, no. 9 (2018): 3067-3076.

[13] R. I. Nurieva, P. Treuting, J. Duong, R. A. Flavell, and C. Dong, “Inducible Costimulator Is Essential for Collagen-induced Arthritis,” Journal of Clinical Investigation 111, no. 5 (2003): 701-706.

[14] P. Conigliaro, P. Triggianese, E. De Martino, et al., “Challenges in the Treatment of Rheumatoid Arthritis,” Autoimmunity Reviews 18, no. 7 (2019): 706-713.

[15] X. Tian, M. Li, and X. Zeng, “The Current Status and Challenges in the Diagnosis and Treatment of Rheumatoid Arthritis in China: An Annual Report of 2019,” Rheumatol Immunol Res 2, no. 1 (2021): 49-56.

[16] S. M. Haikal, N. F. Abdeltawab, L. A. Rashed, T. I. Abd El-Galil, H. A. Elmalt, and M. A. Amin, “Combination Therapy of Mesenchymal Stromal Cells and Interleukin-4 Attenuates Rheumatoid Arthritis in a Collagen-Induced Murine Model,” Cells 8, no. 8 (2019): 823.

[17] C. S. Chambers, V. Holeckova, L. Petraskova, et al., “The silymarin Composition… and Why Does It Matter,” Food Research International 100 (2017): 339-353. Pt 3.

[18] J. A. Sanchez Garcia and D. Santiago Laguna, “[Action of silymarin on the fatty acid composition of the hepatic lipids of estrogenized chickens],” Archivos De Farmacologia Y Toxicologia 7, no. 1 (1981): 143-150.

[19] A. Paradowska-Gorycka, A. Wajda, K. Romanowska-Prochnicka, et al., “Th17/Treg-Related Transcriptional Factor Expression and Cytokine Profile in Patients with Rheumatoid Arthritis,” Frontiers in immunology 11 (2020): 572858.

[20] P. Luo, P. Wang, J. Xu, et al., “Immunomodulatory Role of T Helper Cells in Rheumatoid Arthritis: A Comprehensive Research Review,” Bone Joint Res 11, no. 7 (2022): 426-438.

[21] T. Fu, Q. He, and P. Sharma, “The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy,” Cancer Research 71, no. 16 (2011): 5445-5454.

[22] L. C. Pollard, “Inhibiting Costimulatory Activation of T Cells: A Viable Treatment Option for Rheumatoid Arthritis?,” Drugs 67, no. 1 (2007): 1-9.

[23] H. Zhang, F. Li, J. Cao, et al., “A Chimeric Antigen Receptor With Antigen-independent OX40 Signaling Mediates Potent Antitumor Activity,” Science Translational Medicine 13, no. 578 (2021): eaba7308.

[24] Y. Choi, Y. Shi, C. L. Haymaker, A. Naing, G. Ciliberto, and J. Hajjar, “T-cell Agonists in Cancer Immunotherapy,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e000966.

[25] R. Yang, L. Sun, C. F. Li, et al., “Galectin-9 Interacts With PD-1 and TIM-3 to Regulate T Cell Death and Is a Target for Cancer Immunotherapy,” Nature Communications 12, no. 1 (2021): 832.

[26] G. J. Webb, G. M. Hirschfield, and P. J. Lane, “OX40, OX40L and Autoimmunity: A Comprehensive Review,” Clinical Reviews in Allergy & Immunology 50, no. 3 (2016): 312-332.

[27] I. B. McInnes and G. Schett, “Pathogenetic Insights From the Treatment of Rheumatoid Arthritis,” Lancet 389, no. 10086 (2017): 2328-2337.

[28] L. Aragoneses-Fenoll, M. Montes-Casado, G. Ojeda, et al., “ETP-46321, a Dual p110alpha/Delta Class IA Phosphoinositide 3-kinase Inhibitor Modulates T Lymphocyte Activation and Collagen-induced Arthritis,” Biochemical Pharmacology 106 (2016): 56-69.

[29] Y. Wang, H. Guo, Z. Liang, et al., “Sirolimus Therapy Restores the PD-1+ICOS+Tfh:CD45RA-Foxp3(high) Activated Tfr Cell Balance in Primary Sjogren's Syndrome,” Molecular Immunology 147 (2022): 90-100.

[30] X. Lv, L. Wang, X. Zou, and S. Huang, “Umbilical Cord Mesenchymal Stem Cell Therapy for Regenerative Treatment of Rheumatoid Arthritis: Opportunities and Challenges,” Drug Des Devel Ther 15 (2021): 3927-3936.

[31] L. Wang, S. Huang, S. Li, et al., “Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study,” Drug Des Devel Ther 13 (2019): 4331-4340.

[32] Z. Wang, C. Chai, R. Wang, et al., “Single-cell Transcriptome Atlas of human Mesenchymal Stem Cells Exploring Cellular Heterogeneity,” Clinical and translational medicine 11, no. 12 (2021): e650.

[33] Z. Wang, X. Li, J. Yang, et al., “Single-cell RNA Sequencing Deconvolutes the in Vivo Heterogeneity of human Bone Marrow-derived Mesenchymal Stem Cells,” Int J Biol Sci 17, no. 15 (2021): 4192-4206.

[34] O. P. Gupta, S. Sing, S. Bani, et al., “Anti-inflammatory and Anti-arthritic Activities of silymarin Acting Through Inhibition of 5-lipoxygenase,” Phytomedicine 7, no. 1 (2000): 21-24.

[35] Y. Xie, S. L. Feng, C. T. Mai, et al., “Suppression of Up-regulated LXRalpha by silybin Ameliorates Experimental Rheumatoid Arthritis and Abnormal Lipid Metabolism,” Phytomedicine 80 (2021): 153339.

[36] T. Ito, S. Hanabuchi, Y. H. Wang, et al., “Two Functional Subsets of FOXP3+ Regulatory T Cells in human thymus and Periphery,” Immunity 28, no. 6 (2008): 870-880.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.